MVRBF News and Press, Medivir B From 04/16/21

Medivir AB (MVRBF) has appointed Magnus Christensen, the company's CFO, as interim CEO.Magnus has been CFO of the company since 2019 and in parallel will retain his role as CFO. Magnus succeeds Yilmaz Mahshid.The board has initiated the recruitment process for a new CEO. For further de...

Medivir appoints Magnus Christensen as interim CEO PR Newswire STOCKHOLM , April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen , the company's CFO, as interim CEO o...

Medivir 2020 Annual Report published PR Newswire STOCKHOLM , April 6, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com . In the spri...

Number of shares and votes in Medivir PR Newswire STOCKHOLM , March 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously ann...

Medivir AB (MVRBF) CEO Yilmaz Mahshid is resigning from the company effective May 5 for personal reasons.The company's board proposes that he be elected as a board member and Uli Hacksell be elected chairman.Mahshid was appointed CEO in May 2020.Medivir's board will appoint an interim CEO aft...

Resolutions at the extraordinary general meeting in Medivir on 13 January 2021 PR Newswire HUDDINGE, Sweden , Jan. 13, 2021 /PRNewswire/ -- Resolution regarding reduction of the share capital without cancellation of shares The extraordinary general ...

Medivir AB (MVRBF) enters exclusive licensing agreement, through which IGM Biosciences (IGMS), will receive global  development rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) ...

Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant - Medivir to Receive an Upfront Payment, as Well as Milestone Payments and Royalties - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors PR Newswi...

Notice of extraordinary general meeting of Medivir AB (publ) HUDDINGE, Sweden , Dec. 11, 2020 /PRNewswire/ -- The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm , are hereby summoned to the extraordinary general me...

Medivir strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant STOCKHOLM , Dec. 11, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Comp...